Liprolog (Insulin Lispro)

• Liprolog, a rapid‑acting insulin analog, works within the insulin‑dependent glucose regulation pathway to lower blood sugar levels.
• Diabetes mellitus type 1: provides mealtime glucose control to reduce hyperglycaemia.
• Diabetes mellitus type 2: assists in achieving post‑prandial glucose targets when diet, exercise, and oral agents are insufficient.

• Insulin lispro binds to the insulin receptor on cell membranes, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling cascades that increase glucose transporter (GLUT4) translocation to the cell surface, promote glycogen synthesis in liver and muscle, and suppress hepatic glucose production, resulting in rapid reduction of plasma glucose.

Common Side Effects

• Hypoglycaemia: low blood glucose episodes, especially if meals are missed.
• Injection‑site reactions: redness, swelling, or itching at the injection site.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects

• Severe hypoglycaemia leading to seizures or loss of consciousness.
• Anaphylactic reaction: hives, swelling, difficulty breathing.
• Edema: abnormal fluid accumulation, particularly in the lower extremities.

When using Liprolog, consider the following safety measures.

• Hypoglycaemia risk: monitor blood glucose frequently, especially before meals and physical activity.
• Renal impairment: adjust dose as reduced clearance may increase insulin exposure.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Alcohol consumption: can mask hypoglycaemia symptoms, requiring closer glucose monitoring.
• Concomitant beta‑blockers: may blunt typical hypoglycaemia warning signs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liprolog may interact with several medicines; awareness helps maintain safe therapy.

Major Interactions (Avoid)

• Sulfonylureas: combined use markedly increases hypoglycaemia risk.
• Beta‑blockers: can conceal hypoglycaemia symptoms, complicating detection.
• Intravenous glucose infusions: may require insulin dose reduction.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may enhance insulin sensitivity, necessitating dose review.
• Thiazide diuretics: can raise blood glucose, potentially requiring higher insulin doses.
• Corticosteroids: may increase insulin requirements due to hyperglycaemic effect.